Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function : Post hoc analyses of the EURIDIS-ADONIS trials
Background: The use of antiarrhythmic drugs (AADs) in patients with chronic kidney disease (CKD) is complex because impaired renal clearance can cause increased drug levels, and risk of intolerance or adverse events. Due to the propensity for CKD to occur alongside atrial fibrillation/atrial flutter (AF/AFL), it is essential that AAD safety and efficacy are assessed for patients with CKD. Hypothes